S36 EORTC Cutaneous Lymphoma Task Force Meeting 2019 abstract book | European Journal of Cancer 119S1 (2019) S1–S44 098 Contemporary treatment patterns and response in relapse/refractory cutaneous T-cell lymphoma (CTCL) in clinical practice in France, Germany Italy, Spain and the United Kingdom T. Illidge 1 , M. Bagot 2 , N. Waser 3 , M. He 3 , T. Li 3 , R. Sambrook 3 , A. Zomas 4 , F. Trinchese 4 , F. Gavini 4 , M. Little 5 , P. Ortiz 6 , N. Pimpinelli 7 , M. Dalal 5 , C. Assaf 8 1 University of Manchester, Christie Hospital, Manchester, UK 2 Hôpital Saint-Louis, Paris, France 3 ICON Plc, Vancouver, BC, Canada 4 Takeda Pharmaceuticals International AG, Glattpark-Opfikon, Zurich, Switzerland 5 Millennium Pharmaceuticals, Inc., Cambridge, MA, USA 6 Hospital Universitario 12 de Octubre, Facultad de Medicina, Universidad Complutense, Avenide de Cordoba, Madrid, Spain 7 Hospital P Palagi, Firenze, Italy 8 HELIOS Klinikum Krefeld, Krefeld, Germany Background and aim: CTCL is a rare hematological malignancy in the skin lymphoid tissue whose treatment remains diverse and patient tailored. The objective was to describe treatment patterns and outcomes in CTCL patients who were refractory or had relapsed after a systemic therapy. Methods: A retrospective chart review study was conducted at 27 sites in Europe. Patients enrolled had a diagnosis of CTCL, a prior course of systemic therapy and proved to be relapsed/refractory (R/R) prior to 1 January 2016. For primary cutaneous anaplastic large-cell lymphoma (pcALCL), R/R following radiotherapy qualified patients for inclusion. Results: This study included 157 patients with a median age of 56.0 years. The median follow-up was 3.2 years (range 0–26) from the date of R/R (index date). In total 151/157 patients received further treatment after the index date, 90% received systemic treatment in routine practice, 5% were treated in a clinical trial, and 5% received a stem-cell transplant. Common systemic therapies were single agent (non-methotrexate) chemotherapy (23.2%), combination chemotherapy (17.6%), bexarotene-based regimens (22.4%) and methotrexate monotherapy (12.0%). Overall, 48% displayed an objective response while 21.9% experienced progression. The median time to second R/R was 11.2 months (range 0.0–174.6). Conclusions: This study reveals heterogeneity of systemic therapies and suggests that despite the application of chemotherapy, patients progressed after treatment for R/R and experienced a second R/R within less than one year. These results indicate that the clinical burden of CTCL is likely to be considerable in Europe, and recently approved targeted agents may assist in addressing this problem. 099 Systemic rituximab in the treatment of indolent primary cutaneous B-cell lymphomas C. Muniesa 1 , E. Domingo 2 , R. Fornons 1 , Y. Peñate 3 , T. Estrach 4 , D. Ramón 5 , S. Medina 6 , A. Flórez 7 , P. Ortiz 8 , P. Sánchez 9 , I. Torres 10 , E. Acebo 11 , I. Yanguas 12 , R. Fernández de Misa 13 , M. Blanes 14 , A. Zayas 15 , MA. Descalzo 16 , I. Garcia-Doval 16 , O. Servitje 1 ; Spanish Cutaneous Lymphoma Group 1 Hospital Universitari de Bellvitge, Spain 2 Hospital Duran i Reynals. Institut Català d´Oncologia, Spain 3 Complejo Hospitalario Insular Materno-Infantil, Spain 4 Hospital Clínic de Barcelona, Spain 5 Hospital Clínico de Valencia, Spain 6 Hospital de Alcalá, Spain 7 Complexo Hospitalario de Pontevedra, Spain 8 Hospital Universitario Doce de Octubre, Spain 9 Hospital General de Ciudad Real, Spain 10 Hospital La Fe, Spain 11 Hospital de Cruces, Spain 12 Complejo Hospitalario de Navarra, Spain 13 Hospital Nª Señora de la Candelaria, Spain 14 Hospital General de Alicante, Spain 15 Hospital Universitario Dr Peset, Spain 16 Unidad de Investigación de la AEDV, Spain Introduction: Systemic rituximab has been proposed in the treatment of indolent primary cutaneous B-cell lymphoma (PCBCL) with multiple lesions where local treatment is not indicated. However, little information is available in the literature. Aim: The aim of the study was to evaluate the efficacy and safety of systemic rituximab in a series of patients from the Spanish Cutaneous Lymphoma Group. Material and Methods: Patients with primary cutaneous marginal zone B-cell lymphoma (PCMZBCL) and primary cutaneous follicular B-cell lymphoma (PCFBCL) treated with systemic rituximab were retrospectively reviewed from 2006 to 2018. Results: Fifty-three patients treated with systemic rituximab in mono- therapy were included. Twenty-nine were PCFBCL and 24 PCMZBCL. There were 37 males with a median age of 53 years (23–84 years). All cases received four intravenous weekly infusions rituximab at a dose of 375 mg/m 2 /day. The overall response rate was of 98%, 36 patients (68%) achieved complete response and 16 patients (30%) partial response. Twenty cases (38%) experienced a relapse. There were no significant differences in the duration of response among patients with PCMZBCL and PCFBCL. Treatment was well tolerated in most patients. After a median follow-up of 8.8 years, 35 (66%) patients had no lymphoma lesions, 12 patients (21%) were alive with disease and 1 patient died of the disease. Conclusions: These results suggest that systemic rituximab is an effective and safe treatment for indolent PCBCL. 100 Treatment of Sézary syndrome with alemtuzumab: a case series (2009–2019) I. Fernandes, R. Cabral, M. Lima Multidisciplinary Out Clinic for Cutaneous Lymphomas and Mastocytosis, Centro Hospitalar do Porto – Hospital de Santo António, Porto, Portugal Unit for Multidisciplinary Research in Biomedicine, Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal Introduction: Sézary syndrome (SS) is a rare leukemic type of cutaneous T-cell lymphoma. Due to its rarity, controlled clinical trials are almost non-existent and treatment recommendations are largely based on retrospective studies and expert opinions. Objectives: To assess the effectiveness of low-dose alemtuzumab therapy in patients with SS. Methods: Retrospective study of patients with SS treated with alemtuzumab in a multidisciplinary out clinic for cutaneous lymphomas of a tertiary referral hospital, from 2009 to 2019. Clinical and hematological responses were evaluated using skin and pruritus score systems and through the quantification of Sézary cells by flow cytometry in peripheral blood. Results: Twenty-eight patients with SS were treated with low-dose subcutaneous alemtuzumab (10 mg, 3 times a week over 6 or 12 weeks). Alemtuzumab was used as a first-line therapy in 20 patients. Twenty patients (71%) responded to treatment. Of these, fifteen (75%) achieved complete clinical and hematological response. Remission was sustained, with a median time to relapse of 11 months. Twelve patients received a